Off-label use of an automated insulin delivery system in pregnant women with type 1 diabetes

Lara Albert; Ana Romero; Ismael Capel; Albert Cano; David Subías; Laia Casamitjana; Isabel Mazarico; Mercedes Rigla

doi:10.1016/j.diabres.2023.110800

Off-label use of an automated insulin delivery system in pregnant women with type 1 diabetes

Diabetes Res Clin Pract. 2023 Aug:202:110800. doi: 10.1016/j.diabres.2023.110800. Epub 2023 Jun 24.

Authors

Lara Albert¹, Ana Romero², Ismael Capel², Albert Cano², David Subías², Laia Casamitjana², Isabel Mazarico², Mercedes Rigla²

Affiliations

¹ Endocrinology and Nutrition Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Parc Taulí 1, 08208 Sabadell, Barcelona, Spain. Electronic address: lalbert@tauli.cat.
² Endocrinology and Nutrition Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Parc Taulí 1, 08208 Sabadell, Barcelona, Spain.

PMID: 37364659
DOI: 10.1016/j.diabres.2023.110800

Abstract

Using commercially available automated insulin delivery (AID) systems for treating type 1 diabetes during pregnancy remains controversial. This retrospective study assessed six pregnant women with type 1 diabetes who underwent AID therapy. Our observations revealed that AID treatment, in most cases, did not achieve the desired glycemic targets for pregnancy.

Keywords: Advanced hybrid closed-loop; Automated insulin delivery; Pregestational diabetes; Pregnancy care; Pregnancy-associated diabetes; Type 1 diabetes.

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 1* / drug therapy
Female
Humans
Hypoglycemic Agents / therapeutic use
Insulin / therapeutic use
Insulin Infusion Systems
Off-Label Use
Pregnancy
Pregnant Women
Retrospective Studies

Substances

Hypoglycemic Agents
Insulin
Blood Glucose